Teva Pharmaceutical Industries Ltd. TEVA
We’re very interested in TEVA as a potential bottom bounce play. The stock registered new 52-week lows midway through last week, and has exhibited a solid level of support. Trending up slightly in the premarket, we’re going to be tracking a pair of June options contracts to coincide with what could easily be a significant rebound.
Our specific targets are going to be the TEVA 06/28 $12.50 & $13 Calls, which could present us with sizable opportunities to profit
Sprint Corp. S
We’re also going to set our sights on a range of Sprint options as the company attempts to gain FCC and DOJ approval on its $26B proposed merger with T-Mobile. The review period ends in June, but we’re more interested in the short term capability of the stock to provide us with quick strike chances. We’re going to radar the S Weekly $7-8 Calls.
Adverum Biotechnologies, Inc. ADVM – Review
A stock we recently began tracking, ADVM has been in a fairly continual uptrend since we signaled it for observation on the morning of April 17th. In the last month, the stock has made considerable bullish strides.
From the low we observed on the day of our initial alert, at 5.44, ADVM has gone on to record a high of 9.17. That comes out to an increase of 69%
TOPS, GERN, GMO, AMRH, TRQ, CREX, FUN, ICON, SQQQ, TMUS, INDY
Amplitech Group, Inc. AMPG – Update
We were all over AMPG once again last week, as we have been since the beginning of April when we initiated coverage on the stock. The move on Friday followed the news that the company virtually doubled their yearly expected sales via acquisition of a long-established, privately-held company.
AMPG made a 15% intraday push to a new high of .063 which works out to an overall increase of 47% over the .043 low we observed on the day of our initial report on the company (04/01/19). It also came with the biggest single-session volume recorded over these past six weeks.
Friday’s gains pushed AMPG‘s market cap above the $3M mark, although we would argue that even at that price, the stock is still grossly undervalued at present. Especially when one considers that it’s notably less than the combined expected annual sales of AMPG and the pending acquisition target, which you can read about in the link to the news above, or in the 8-K filed this morning.
We remain excited for the future potential of this company, and its stock. Stay tuned for future updates and be sure to commence your own due diligence, starting at AmpliTechInc.com.
SPDR S&P500 ETF (SPY) – Recap
Along with our coverage of AMPG on Friday morning, we also included a fresh options idea for the SPY that was incredibly successful, and reinforcing the strength of our commitment to producing the very best ideas that we can.
We cited the SPY Weekly $284-285.50 Calls, and with the help of a strong second half of the day for the markets as a whole, yielded the following enormous gain opportunities:
$284 Calls – Range: .59-4.82 – Max Gain: 717%
$284.50 Calls – Range: .43-4.20 – Max Gain: 877%
$285 Calls – Range: .30-3.84 – Max Gain: 1180%
$285.50 Calls – Range: .21-3.29 – Max Gain: 1467%
TVIX, AXNX, IZEA, MOSY, SQQQ, CPRX